Trial Profile
Phase II study evaluating safety and efficacy of maintenance therapy with bortezomib, lenalidomide and dexamethasone for multiple myeloma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Jun 2017
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms SMUIM4-MM01
- 12 Jun 2016 Status changed from recruiting to completed according to results presented at the 21st Congress of the European Haematology Association.
- 28 Jun 2012 New trial record